Fasting insulin vs HbA1c vs glucose: Which shows metabolic aging first?

Insulin resistance can precede a formal type 2 diabetes diagnosis by 10 to 15 years — sometimes more. In that long silent window, the pancreas compensates, blood sugar stays in range, and routine panels look reassuring. The reason is uncomfortable: most clinicians never order fasting insulin, so the earliest warning sign is never measured.

That leaves millions of adults with a “normal” annual check-up — fasting glucose fine, HbA1c fine — while the metabolism is already drifting. By the time glucose or HbA1c rises, arterial stiffening, ectopic fat, and glycation damage have had a decade to accumulate.

This article ranks the three markers in the order they actually change during metabolic aging, shows you how to sequence testing, and explains what to do when results disagree. The goal is simple: catch the drift when it is still fully reversible.

What you’ll learn:

Which of the three markers moves first, second, and last during metabolic aging
How to read a head-to-head comparison of cost, sensitivity, and actionability
How to sequence testing — and how to interpret HOMA-IR from the numbers you already have
When HbA1c or fasting glucose can mislead you, and how to resolve discordant results

Quick answer

In the metabolic aging timeline, fasting insulin rises first — often 10 to 20 years before any glycemic marker flags. Postprandial glucose variability (captured by CGM or an oral glucose tolerance test) comes next. Fasting glucose drifts up third, usually once beta-cell compensation starts to fail. HbA1c is the last to move, because it is a 2-to-3-month weighted average weighted toward recent weeks and it reflects established chronic hyperglycemia. If you want to see metabolic aging early, you have to measure insulin.

The three markers, defined

Before comparing them, let’s be precise about what each test actually measures — and why the “normal” population ranges are not the same as “optimal for longevity.”

Fasting glucose

Fasting plasma glucose is the concentration of sugar in your blood after 8 to 12 hours without food. It is the cheapest, most universal metabolic test in medicine.

Units: mg/dL (primary) or mmol/L (secondary, multiply mg/dL by 0.0555).
ADA diagnostic thresholds: normal below 100 mg/dL (5.6 mmol/L); prediabetes 100 to 125 mg/dL (5.6 to 6.9 mmol/L); diabetes at or above 126 mg/dL (7.0 mmol/L) confirmed on two occasions.
Longevity-optimal band: roughly 72 to 85 mg/dL (4.0 to 4.7 mmol/L), based on large cohort data linking fasting glucose in the high-normal range to increased cardiovascular and all-cause mortality.

For the full deep dive, see glucose and aging.

HbA1c (glycated hemoglobin)

HbA1c measures the percentage of hemoglobin in your red blood cells that has been irreversibly glycated by circulating glucose. Because red cells live roughly 90 to 120 days, HbA1c is a weighted average of blood glucose over the past 2 to 3 months — weighted toward the most recent 30 days.

Units: % (NGSP/DCCT, primary) or mmol/mol (IFCC, secondary). Approximate conversion: mmol/mol = (% − 2.15) × 10.929.
ADA thresholds: normal below 5.7% (39 mmol/mol); prediabetes 5.7 to 6.4% (39 to 46 mmol/mol); diabetes at or above 6.5% (48 mmol/mol).
Longevity-optimal band: approximately 4.9 to 5.4% (30 to 36 mmol/mol). Below 4.9% is not automatically better — very low values can reflect anemia, hemolysis, or accelerated red cell turnover.

For context on the full curve and U-shape, see HbA1c and metabolic aging.

Fasting insulin

Fasting insulin is the amount of insulin the pancreas must secrete to hold glucose steady at rest. When cells listen poorly (insulin resistance), the pancreas shouts louder — insulin climbs while glucose stays normal.

Units: µIU/mL (primary) or pmol/L (secondary, multiply µIU/mL by 6.945).
Lab “normal” range: typically 2 to 25 µIU/mL (14 to 174 pmol/L), but this range includes people already insulin-resistant.
Longevity-optimal band: roughly 2 to 6 µIU/mL (14 to 42 pmol/L); centenarian studies cluster below 5 µIU/mL (35 pmol/L).

For age-stratified reference values and a breakdown of what your specific number means by decade, see fasting insulin normal range by age.

For the standalone explainer, see fasting insulin as a longevity biomarker.

The metabolic aging timeline: what moves first

Metabolic dysfunction does not appear overnight. It follows a reproducible sequence, documented over decades by DeFronzo and others.

Insulin sensitivity drops in muscle and liver — often driven by ectopic fat, inactivity, poor sleep, chronic stress, or aging itself.
Fasting insulin rises to compensate. Blood glucose stays perfectly normal. This phase can last 10 to 20 years.
HOMA-IR increases — the product of fasting insulin and fasting glucose captures the compensation.
Postprandial glucose spikes appear — the pancreas can still handle baseline but struggles with meal loads. A CGM or an oral glucose tolerance test catches this; fasting labs miss it entirely.
Fasting glucose creeps up — usually into the 90s mg/dL (5.0 to 5.5 mmol/L), then into the prediabetic 100 to 125 mg/dL (5.6 to 6.9 mmol/L) range.
HbA1c drifts — from the 5.0 to 5.3% optimal zone toward 5.7% and beyond.
Beta-cell exhaustion — eventually, insulin production itself declines, and overt type 2 diabetes is diagnosed.

The uncomfortable implication: fasting glucose and HbA1c are lagging indicators. By the time either flags, you are deep in step 5 or 6 of a 7-step process that started decades earlier.

Head-to-head comparison

Feature	Fasting glucose	HbA1c	Fasting insulin
What it measures	Blood sugar right now (after fasting)	2-to-3-month glucose average	Insulin needed to keep glucose stable
Longevity-optimal	72 to 85 mg/dL (4.0 to 4.7 mmol/L)	4.9 to 5.4% (30 to 36 mmol/mol)	2 to 6 µIU/mL (14 to 42 pmol/L)
Cost (typical)	Very low	Low	Moderate
Availability	Universal	Universal	Not routine; must request
Sensitivity to early dysfunction	Low — rises late	Very low — lagging by months	High — moves years before others
Day-to-day variability	High (stress, sleep, last meal)	Very low	Moderate
Actionability	Moderate — blunt signal	Moderate — slow feedback	High — responds to diet, sleep, exercise within weeks
Best use	Baseline screen, diabetes diagnosis	Confirm chronic hyperglycemia	Early detection, longevity optimization

No single marker wins on every axis. Glucose is cheap and ubiquitous but late. HbA1c integrates over time but lags. Fasting insulin catches the problem early but costs more and is rarely ordered. The right strategy is to combine them — starting with the one that moves first.

Why HbA1c alone can miss years of damage

HbA1c is often marketed as “the” metabolic marker, but its mechanism guarantees it will be late to the party. Red blood cells live about 90 to 120 days, and glycation accumulates proportionally to time and glucose exposure. That means:

HbA1c reflects the past 8 to 12 weeks of glycemia, weighted toward the last 4 weeks. A recent dietary reset can lower it; a rough month can raise it. It is a movie, but a blurry one.
It stays “normal” until average glucose has been elevated for months. Early-stage insulin resistance — where fasting glucose is still fine and spikes are contained by a hyperactive pancreas — produces a perfectly normal HbA1c.
It can be distorted by red cell biology. Anemia, hemolysis, recent blood loss, iron deficiency, chronic kidney disease, pregnancy, and hemoglobin variants all shift HbA1c up or down independently of glucose. A “low” HbA1c in someone with iron-deficiency anemia is not protective.

For people over 40 tracking biological age with PhenoAge, HbA1c is useful as confirmation of chronic dysglycemia — but never as first-line early detection.

Why fasting glucose alone can mislead

Fasting glucose looks like the obvious early marker — it’s simple, it’s cheap, it’s on every panel. But the same compensation that makes insulin rise early is what keeps glucose normal for so long.

Compensated hyperinsulinaemia hides the signal. The pancreas secretes enough extra insulin to clamp fasting glucose in the 80s mg/dL (4.4 to 4.9 mmol/L) even when insulin resistance is severe. The tank level looks fine; the pump is screaming. If your lab panel shows this exact pattern, use the dedicated guide to normal fasting glucose with high insulin.
A single value is noisy. Cortisol, poor sleep, a hard workout the night before, late dinner, coffee timing, even a cold — any of these can swing fasting glucose by 10 to 15 mg/dL (0.6 to 0.8 mmol/L). One “high” reading is not a diagnosis; one “normal” reading is not reassurance. For age-stratified targets and risk zones for fasting glucose, including what “drifting” looks like by decade, see our dedicated guide.
Postprandial spikes are invisible. Someone with a fasting glucose of 88 mg/dL (4.9 mmol/L) can spike to 180 mg/dL (10 mmol/L) after a bowl of pasta and never know it without a continuous glucose monitor. If HbA1c is still normal in that situation, the normal HbA1c with glucose spikes guide explains how to verify the pattern.

Fasting glucose remains essential — you need it to calculate HOMA-IR and to screen for overt diabetes — but treating it as a standalone early-warning system is how decades of metabolic drift get missed.

Why fasting insulin changes everything

Fasting insulin is the only one of the three markers that responds to the underlying defect (loss of insulin sensitivity) rather than to its downstream consequence (hyperglycemia).

It moves early. Prospective cohort studies find hyperinsulinaemia detectable 10 to 20 years before fasting glucose or HbA1c leaves the normal range.
It is quantitatively sensitive. A rise from 4 to 10 µIU/mL (28 to 70 pmol/L) is a meaningful signal, even though both values are labeled “normal” on a standard lab report.
It responds quickly to intervention. Insulin can drop 30 to 50% within 4 to 8 weeks of consistent resistance training, improved sleep, and reduced refined carbohydrate intake — long before HbA1c has had time to move. See how to improve insulin sensitivity for the evidence-based playbook.
It anchors the broader picture. Combined with fasting glucose it yields HOMA-IR; combined with triglycerides it yields the TyG index; combined with C-peptide it distinguishes compensated from failing beta cells.

The catch: most insurance-driven panels never include it. You usually have to ask explicitly or order it through a direct-to-consumer lab.

How to sequence your testing

Order matters, and so does cost. Here is a pragmatic sequence that maximizes information per dollar.

Start with a paired fasting insulin + fasting glucose. Draw both from the same sample after 10 to 12 hours of fasting, no exercise the prior evening, normal sleep. Calculate HOMA-IR (formula below).
Add HbA1c as longer-term confirmation. Run it at the same draw or shortly after. It confirms whether any dysglycemia is chronic or recent.
If results are discordant, order a CGM or an OGTT. Example discordances: HOMA-IR elevated but HbA1c and glucose normal (early insulin resistance — likely real), or HbA1c elevated with normal fasting glucose and insulin (check for anemia, hemoglobinopathy, or postprandial spikes). A 2-week CGM resolves most ambiguity by revealing meal-by-meal behavior.
Retest the marker that moved first. If fasting insulin was the anomaly, recheck it every 3 to 6 months; it gives the fastest feedback on lifestyle changes. HbA1c is only worth rechecking every 3 to 4 months — less frequently is wasted money.
Track trajectory, not single values. Three data points in an upward trend — even within “normal” — matter more than one isolated value.

This sequence respects the biology: catch the early signal with insulin, confirm with HbA1c, disambiguate with CGM only when needed.

How to interpret HOMA-IR

HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) converts two numbers you already have into a single estimate of insulin resistance.

Formula

With glucose in mg/dL: HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mg/dL) / 405
With glucose in mmol/L: HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mmol/L) / 22.5

Interpretation bands (approximate, non-diabetic adults)

HOMA-IR	Interpretation
Below 1.0	Optimal insulin sensitivity
1.0 to 1.9	Average; acceptable for most adults
2.0 to 2.9	Early insulin resistance; lifestyle priority
At or above 3.0	Established insulin resistance; clinical follow-up warranted

Worked example. Fasting insulin 9 µIU/mL, fasting glucose 95 mg/dL (5.3 mmol/L): HOMA-IR = (9 × 95) / 405 ≈ 2.11. Technically “prediabetic physiology,” yet every individual number on the lab report likely reads “normal.” This is exactly the pattern the sequencing approach is designed to catch.

HOMA-IR is a static estimate; it correlates well with the hyperinsulinemic-euglycemic clamp (the gold standard for insulin sensitivity) at the population level but has wider variance in individuals. It is still the best low-cost tool you have, and it fits inside a single blood draw. For the upstream pathway biology, see insulin/IGF-1 signaling and longevity.

How SuperAge tracks metabolic aging

SuperAge uses the PhenoAge algorithm as its biological age engine. PhenoAge takes fasting glucose (alongside albumin, creatinine, CRP, lymphocytes, MCV, red cell distribution width, alkaline phosphatase, and white blood cell count) and outputs a biological age that has been validated against mortality in large cohorts.

The app integrates this with HealthKit signals — resting heart rate, VO2 max, weight trajectory, daily activity — so your metabolic number sits next to the cardiovascular and behavioral signals that actually move it. You enter your lab values, SuperAge computes your PhenoAge, and you track whether lifestyle changes are moving the needle over months, not years.

Fasting insulin is not yet part of the PhenoAge formula (it was derived from NHANES variables that did not include insulin), but SuperAge lets you log it alongside your biological age to watch the earliest marker trend together with the clinical one.

Download SuperAge on the App Store.

Frequently asked questions

Can you have insulin resistance with a normal HbA1c?

Yes — and it is common. Early to mid-stage insulin resistance is defined by the pancreas successfully compensating: insulin rises, glucose stays normal, HbA1c stays normal. Studies using the sugar-and-aging framework consistently find meaningful insulin resistance in people with HbA1c below 5.5% (37 mmol/mol). Normal HbA1c rules out chronic hyperglycemia; it does not rule out insulin resistance.

Is fasting insulin worth the extra cost?

If you are under 50 and the panel is your once-a-year check, yes — it is the only way to see the process that starts first. Fasting insulin typically adds 20 to 60 USD / EUR to a lipid-and-glucose panel. Relative to a CGM (150 to 300 USD / EUR) or a clamp study (research-only), it is the highest information-per-dollar early-detection test available.

How often should you test?

A reasonable cadence for an asymptomatic adult with no prior findings: fasting insulin + glucose + HbA1c once a year. If any marker is in the “early drift” zone — HOMA-IR 1.5 to 2.5, fasting glucose 90 to 99 mg/dL (5.0 to 5.5 mmol/L), or HbA1c 5.4 to 5.6% (36 to 38 mmol/mol) — retest fasting insulin and glucose every 3 to 6 months and HbA1c every 3 to 4 months to track the trajectory.

Which should I prioritize if I can only afford one?

Fasting insulin paired with fasting glucose from the same draw — this single paired test gives you HOMA-IR, which is more informative than either glucose or HbA1c alone for detecting early metabolic aging.

Can a low HbA1c be a bad sign?

Occasionally, yes. HbA1c below 4.9% (30 mmol/mol) in a non-athletic adult can reflect shortened red blood cell lifespan — hemolysis, occult blood loss, iron deficiency, chronic kidney disease, or certain hemoglobin variants — rather than excellent glycemic control. If your HbA1c is unexpectedly low, check a complete blood count, ferritin, and reticulocyte count before celebrating.

Key takeaways

Fasting insulin moves first — often 10 to 20 years before glucose or HbA1c leaves the normal range.
Postprandial spikes move second — visible only with CGM or an OGTT, not with fasting labs.
Fasting glucose moves third, once beta-cell compensation starts to slip.
HbA1c moves last — a confirmatory, not an early, marker.
Start the sequence with paired fasting insulin + glucose, calculate HOMA-IR, confirm with HbA1c. Escalate to CGM only when results disagree.
Longevity-optimal bands are tighter than diagnostic thresholds: glucose 72 to 85 mg/dL (4.0 to 4.7 mmol/L); HbA1c 4.9 to 5.4% (30 to 36 mmol/mol); insulin 2 to 6 µIU/mL (14 to 42 pmol/L).
Trajectory beats single values. Three rising data points, all within “normal,” are more actionable than one isolated high reading.

This article is for educational purposes only and does not replace professional medical advice. If you have abnormal glucose, HbA1c, or insulin values, consult your healthcare provider.

Start testing the marker that moves first

The earliest signal of metabolic aging is almost certainly not on your annual lab report — because almost no one orders it. Add fasting insulin to your next blood draw, calculate HOMA-IR with the formula above, and log the number alongside your biological age.

Download SuperAge on the App Store to track your PhenoAge and watch your metabolic trajectory in one place.

If HbA1c is already high while fasting glucose is still normal, use HbA1c high but fasting glucose normal to separate post-meal exposure from red blood cell or assay issues.

When the next question is dynamic glucose handling rather than baseline pressure, OGTT vs fasting insulin compares the two test paths.

References

DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. Diabetes Care. 2023;46(Suppl 1):S19-S40.
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.
Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133(2):496-506.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.

If you are comparing a morning glucose rise with post-meal spikes, use Morning glucose spike vs post-meal spike: which matters more? to decide which pattern deserves more attention.

If you are separating appetite signaling from glucose handling, use Leptin resistance vs insulin resistance: how they differ to compare leptin resistance with insulin resistance before choosing what to track.

Measure the marker that moves first — then use the slower markers to confirm what insulin has been telling you all along.